Zephyr Endobronchial Valve (EBV) System
Pulmonx Corporation · Decision date Mar 17, 2026
What did the FDA decide?
FDA records P180002/S030 as a supplement to PMA P180002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 17, 2026.
FDA approval order statement
Removal of the ambient aeration step of the ethylene oxide (EO) sterilization process.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Anesthesiology
- Decision date
- Mar 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180002/S030
- Regulatory pathway
- PMA supplement
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- Decision code
- OK30
- Decision date
- Mar 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Valve, pulmonary.
- Applicant
- Pulmonx Corporation
- Product code
- NJK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P180002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P180002 · Original PMA
Zephyr Endobronchial Valve System
P180002/S030 received
Application receipt date recorded by FDA.
P180002/S030 · FDA decision
30-Day Notice
P180002/S031 · Related supplement
Zephyr Endobronchial Valve (EBV) System
P180002/S032 · Related supplement
Zephyr Endobronchial Valve System
Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Pulmonx Corporation | PMA approval | Jun 29, 2018 | FDA | |
Zephyr Endobronchial Valve (EBV) SystemP180002/S031 | Pulmonx Corporation | PMA supplement | Jun 17, 2026 | FDA |
Zephyr Endobronchial Valve SystemP180002/S032 | Pulmonx Corporation | PMA supplement | Sep 11, 2026 | FDA |
Explore the linked device profile
Other records with product code NJK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Spiration Valve SystemP180007/S016 | Gyrus Acmi, Inc. | PMA supplement | Aug 20, 2026 | FDA |
Spiration Valve System (SVS)P180007/S015 | Gyrus Acmi, Inc. | PMA supplement | May 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pulmonx Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 700 Chesapeake Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P180002/S030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records